I. Ambros

发表

Quality A ssessment o f G enetic M arkers U sed f or Therapy S tratification

F. Speleman, O. Delattre, B. Bernardi, 2003 .

The International Neuroblastoma Pathology Classification (the Shimada system)

K K Matthay, D O Stram, D. Stram, 1999, Cancer.

Nervous system: Peripheral neuroblastic tumours (Neuroblastoma, Ganglioneuroblastoma, Ganglioneuroma)

F. Speleman, P. Ambros, I. Ambros, 2011 .

Genetics and biology of neuroblastoma - an overview

P. Ambros, H. Gadner, R. Ladenstein, 2004 .

181 INVITED International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk grouping (INRG) biology committee

J. Khan, F. Speleman, R. Spitz, 2007 .

Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method : 115 000 screened infants in Austria

L. Parker, P. Ambros, G. Amann, 1996 .

Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy.

W. Gerald, M. Ladanyi, P. Ambros, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

J Khan, S L Cohn, J. Khan, 2009, British Journal of Cancer.

Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation--sign of tumour cell revertance?

H. Kovar, P. Ambros, H. Gadner, 1997, European journal of cancer.

Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?

H. Kovar, P. Ambros, C. Urban, 1995, European journal of cancer.

Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea

P. Ambros, P. Boukamp, A. Kowalska, 2007, Genes, chromosomes & cancer.

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

J. Khan, F. Speleman, M. Fischer, 2012, British Journal of Cancer.

Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.

B. Bernardi, H. Kovar, P. Ambros, 2001, Medical and pediatric oncology.

First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study.

P. Ambros, G. Höfler, G. Amann, 1995, European journal of cancer.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors

P. Ambros, S. Navarro, I. Tadeo, 2016, Oncogene.

Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.

P. Ambros, D. Printz, G. Amann, 1996, The New England journal of medicine.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification

A. Vicha, S. Parodi, G. Tonini, 2014, British Journal of Cancer.